Actionable news
All posts from Actionable news
Actionable news in DVAX: Dynavax Technologies Corporation,

Kite informs no Adcom required; Esperion (ESPR) reports positive hypercholesterolemia data; Gale reverse merger

Price and Volume Movers

Kite Pharma Inc (NASDAQ:KITE) shares closed Tuesday's session up 6% to $120.13. The company announced that the FDA has advised an Advisory Committee Meeting will not be required for its regulatory filing for its CAR-T candidate, Axi-cel, for the treatment of Non-Hodgkin's Lymphoma (NHL). The PDUFA date under priority review is set for November 29, 2017.

Galena Biopharma, Inc.(NASDAQ:GALE) announced a reverse merger with SELLAS Life Sciences Group Ltd, a privately-held company. The combined company will be renamed SELLAS Life Science Group, Inc and is expected to close in 4Q 2017. Galena holders will own 32.5%, of the combined company. Shares of Galena closed down 27% to $0.41 following the news.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares surged during the morning session before retracing gains to close up 15% to $52.13 following its announcement of positive top-line data from its Phase 2 trial (1002-038) of the bempedoic acid / ezetimibe combination plus atorvastatin, versus placebo, in patients with hypercholesterolemia. The trial met the primary endpoint with patients seeing their LDL cholesterol levels fall 64% from baseline levels compared to those on the placebo. The company announced after-hours a public offering of $150m.

Dynavax Technologies Corporation (NASDAQ: DVAX) also announced an offering of $125m of shares of its common stock.

FibroGen, Inc. (NASDAQ:FGEN) shares closed up 48% to $49.50 following...